Nurix Therapeutics reported third-quarter results for the period ended May 31, 2026, with revenue of $9.04M and a net loss of $89.54M, or diluted loss per share of $(0.81), versus revenue of $14.06M, net loss of $43.46M and diluted loss per share of $(0.52) in the year‑ago quarter.
Financial Highlights
- Revenue was $9.04M for Q3 2026, compared with $14.06M in the year‑ago quarter; YoY change (35.6%).
- Net income was a loss of $89.535M for Q3 2026, compared with a loss of $43.464M in the year‑ago quarter; loss widened by $46.071M YoY.
- Diluted earnings per share was $(0.81) for Q3 2026, versus $(0.52) in the year‑ago quarter.
Business Highlights
- Pipeline progress: continued Phase 2 for bexobrutideg and Phase 1 trials for zelebrudomide and NX‑1607, with enrollment and dose escalation advancing.
- Collaborations and licensing: new Roche collaboration for bexobrutideg and ongoing partnerships with Gilead, Sanofi and Pfizer continue to support discovery and provide non‑dilutive funding.
- Revenue mix shift: collaboration revenue declined as initial research terms concluded and license milestone timing reduced 2026 license revenue.
- DEL‑AI platform: ongoing use of the proprietary DEL‑AI discovery platform supports multiple partnered programs and has generated $489M in non‑dilutive proceeds to date.
- Operational scale‑up: increased spending on clinical trials, CMOs and contract research, along with higher personnel and stock‑based compensation to support growth.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.